LEUKEMIA TRANSLOCATIONS-PANEL 3
The panel analyzes genetic alterations associated with leukemia, offering insight into molecular abnormalities that can affect treatment and prognosis.
LEUKEMIA TRANSLOCATIONS-PANEL 3 Package in Mangaluru Overview
What is Leukemia Translocation Panel 3 test?
Leukemia Translocation Panel 3 is a molecular cytogenetic test designed to detect specific chromosomal translocations and gene rearrangements commonly associated with acute and chronic leukemias. These genetic translocations result in fusion genes that play a critical role in the onset, classification, and progression of leukemia. Leukemia Translocation Panel 3 test typically uses RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) or FISH (Fluorescence In Situ Hybridization) to identify these fusion events, providing valuable diagnostic and prognostic information.
Parameters Covered : Gene Covered: (t(1;11) (P32;Q23), t(1;11) (P21;Q23), t (4;11) (Q21;Q23), t (6;11) (Q27;Q23), t(9;11) (P22;Q23), t(10;11) (P12;Q23), t(11;17) (Q23;Q21), t(11;19) (Q23;P13.1), t(11;19) (Q23;P13.3), DUP, MLL (11Q23), t(X;11) (Q13;Q23))
Why consider Leukemia Translocation Panel 3 test?
Leukemia Translocation Panel 3 test can be considered
- To confirm the diagnosis of specific leukemia subtypes based on genetic abnormalities.
- To identify prognostic markers that predict disease behavior and treatment response.
- To help in treatment planning, including the use of targeted therapies (e.g., tyrosine kinase inhibitors).
- To monitor minimal residual disease (MRD) or detect relapse in patients previously treated for leukemia.
Who should get tested for Leukemia Translocation Panel 3 test?
Leukemia Translocation Panel 3 test is generally recommended for:
- Patients suspected or newly diagnosed with acute or chronic leukemia.
- Individuals with abnormal blood counts or bone marrow findings suggesting a hematologic malignancy.
- Patients whose clinicians require molecular confirmation of specific translocations for diagnosis or therapy selection.
- Cases where standard cytogenetic tests are inconclusive.
More Information
OTHER NAMES: Leukemia Molecular panel, Leukemia Prognostic Panel, Leukemia translocations,
Leukemia is a cancer of the blood and bone marrow. In simple terms, cancer is defined as the uncontrolled growth of abnormal cells. Cancer can develop anywhere in the body. In leukemia, this rapid, out-of-control growth of abnormal cells takes place in the bone marrow. These abnormal cells then spill into the bloodstream. Unlike other cancers, Leukemia generally doesn’t form into a mass (tumour) that can be seen in imaging tests, such as X-rays.
No special preparations needed
- Specimen Source
- Preliminary Report
- T(4;11) (q21; Q23)
- T(6;11) (q27; Q23)
- T(9;11) (p22; Q23)
- T(10;11) (p12; Q23)
- T(11;19) (q23; P13.1)
- T(11; 19) (q23; P13.3)
- Rbm15-mkl1 [t(1;22)]
- Dek-can [t( 6;9)]
- Set-can [t(9;9)]
Test code
1627
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Edta Whole Blood | Lavender Vacutainer | 3 ML |
| Heparin Whole Blood | Green Vacutainer | 3 ML |
Specimen stability information
Edta Whole Blood, Heparin Whole Blood
Collection instructions
Clinical History
Specimen rejection criteria
Test run frequency
Every Day TIME - 09:30
Turn around time
7 Working Days
Performing locations
Department
- Advanced Molecular Diagnostics R&d
CPT and Loinc codes
Package price
₹9000
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestLEUKEMIA TRANSLOCATIONS-PANEL 3
₹9000